Syon Capital’s Amicus Therapeutics FOLD Stock Holding History

Syon Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,255	Closed	-$285K	–	612
2024 Q4	$285K	Buy	+30,255	New	+$314K	0.03%	411

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Syon Capital's FOLD Position: Q1 2025 in Review

Syon Capital sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 30,255 shares — an estimated $285K sold.

Syon Capital first reported a position in FOLD in Q4 2024 and held it in 1 quarter. The position peaked at $285K in Q4 2024. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

Syon Capital reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 30,255 Amicus Therapeutics shares in Q1 2025, an estimated $285K.
Syon Capital first reported a position in Amicus Therapeutics in Q4 2024 and held it in 1 quarter.
Syon Capital's Amicus Therapeutics position peaked at $285K in Q4 2024.
286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.